BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...acquired 17.9% in 2009 deal and the rest in 2011 for €1.8 billion ($2.4 billion) GPC Biotech AG...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Menaquinone

...activity in topical applications (See Cover Story). TARGET/MARKER/PATHWAY: Menaquinone LICENSING STATUS: Patent issued; licensed to Genome Pharmaceuticals...
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

With antibiotic discovery coming back into vogue, two groups have literally gone to ground to find new compounds produced by bacteria in the soil. Using designed-for-purpose screening systems, the teams identified two unknown antimicrobial peptides...
BioCentury | May 20, 2013
Company News

Evotec, Harvard deal

...The partners declined to disclose details. Evotec previously partnered on antibiotics deals with GPC Biotech AG (formerly Genome Pharmaceuticals...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...testing for diabetic foot ulcers. It was not the first stumble for Agennix. Its predecessor, GPC Biotech AG...
...of Roche (SIX:ROG; OTCQX:RHBBY) Agennix AG (Xetra:AGX) Germany Cancer 2006 9% 60% Agennix merged with GPC Biotech AG...
BioCentury | Jul 16, 2012
Finance

Venture tracks

...firm's focus on European investments. They were partners at KI Kapital and co-founded cancer play GPC Biotech AG...
BioCentury | May 16, 2011
Strategy

Yakult: Special at Home

...trial is expected to be complete in 2013. In 2007, Yakult did a deal with GPC Biotech AG...
...to ThermoDox, a doxorubicin encapsulated in heat-activated liposomes Ph III for liver cancer July 2007 GPC Biotech AG...
BioCentury | Nov 16, 2009
Company News

Agennix Inc, GPC Biotech deal

...form Agennix AG (Xetra:AGX, Heidelberg, Germany) (see BioCentury, Feb. 23). Agennix Inc ., Houston, Texas GPC Biotech AG...
BioCentury | Oct 19, 2009
Company News

Agennix Inc. management update

...Cancer, Autoimmune, Dermatology Resigning: Atul Varadhachary as president and COO, following the planned merger with GPC Biotech AG WIR...
BioCentury | Jun 15, 2009
Clinical News

Orplatna satraplatin: Preliminary Phase II data

...of Clinical Oncology in conjunction with the American Association for Clinical Oncology meeting in Orlando. GPC Biotech...
...by Genentech Inc. , a unit of Roche (SIX:ROG, Basel, Switzerland), and elsewhere by Roche. GPC Biotech AG...
Items per page:
1 - 10 of 327
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...acquired 17.9% in 2009 deal and the rest in 2011 for €1.8 billion ($2.4 billion) GPC Biotech AG...
BioCentury | Jan 22, 2015
Distillery Therapeutics

Therapeutics: Menaquinone

...activity in topical applications (See Cover Story). TARGET/MARKER/PATHWAY: Menaquinone LICENSING STATUS: Patent issued; licensed to Genome Pharmaceuticals...
BioCentury | Jan 22, 2015
Targets & Mechanisms

Unearthing antibiotics

With antibiotic discovery coming back into vogue, two groups have literally gone to ground to find new compounds produced by bacteria in the soil. Using designed-for-purpose screening systems, the teams identified two unknown antimicrobial peptides...
BioCentury | May 20, 2013
Company News

Evotec, Harvard deal

...The partners declined to disclose details. Evotec previously partnered on antibiotics deals with GPC Biotech AG (formerly Genome Pharmaceuticals...
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...testing for diabetic foot ulcers. It was not the first stumble for Agennix. Its predecessor, GPC Biotech AG...
...of Roche (SIX:ROG; OTCQX:RHBBY) Agennix AG (Xetra:AGX) Germany Cancer 2006 9% 60% Agennix merged with GPC Biotech AG...
BioCentury | Jul 16, 2012
Finance

Venture tracks

...firm's focus on European investments. They were partners at KI Kapital and co-founded cancer play GPC Biotech AG...
BioCentury | May 16, 2011
Strategy

Yakult: Special at Home

...trial is expected to be complete in 2013. In 2007, Yakult did a deal with GPC Biotech AG...
...to ThermoDox, a doxorubicin encapsulated in heat-activated liposomes Ph III for liver cancer July 2007 GPC Biotech AG...
BioCentury | Nov 16, 2009
Company News

Agennix Inc, GPC Biotech deal

...form Agennix AG (Xetra:AGX, Heidelberg, Germany) (see BioCentury, Feb. 23). Agennix Inc ., Houston, Texas GPC Biotech AG...
BioCentury | Oct 19, 2009
Company News

Agennix Inc. management update

...Cancer, Autoimmune, Dermatology Resigning: Atul Varadhachary as president and COO, following the planned merger with GPC Biotech AG WIR...
BioCentury | Jun 15, 2009
Clinical News

Orplatna satraplatin: Preliminary Phase II data

...of Clinical Oncology in conjunction with the American Association for Clinical Oncology meeting in Orlando. GPC Biotech...
...by Genentech Inc. , a unit of Roche (SIX:ROG, Basel, Switzerland), and elsewhere by Roche. GPC Biotech AG...
Items per page:
1 - 10 of 327